Browse: Departments Dates Agencies
SUBJECT CATEGORY: Importer of Controlled Substances; Notice of Registration
DOCUMENT SUMMARY:
By Notice dated July 31, 2007 and published in the Federal Register on August 9, 2007, (72 FR 4485944860), Aptuit (Allendale), Inc., 75 Commerce Drive, Allendale, New Jersey 07401, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II.
The company plans to import the basic class of controlled substance for clinical trials and research.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the
registration of Aptuit (Allendale), Inc. to import the basic class of
controlled substance is consistent with the public interest and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971, at this time. DEA has investigated
Aptuit (Allendale), Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 952(a) and Sec. 958(a), and in accordance with 21 CFR
1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E723978 Filed 121007; 8:45 am]
BILLING CODE 441009P
SUMMARY: Aptuit (Allendale), Inc.,
DOCUMENT BODY 2:
By Notice dated July 31, 2007 and published in the Federal Register on August 9, 2007, (72 FR 4485944860), Aptuit (Allendale), Inc., 75 Commerce Drive, Allendale, New Jersey 07401, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II.
The company plans to import the basic class of controlled substance for clinical trials and research.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the
registration of Aptuit (Allendale), Inc. to import the basic class of
controlled substance is consistent with the public interest and with
United States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971, at this time. DEA has investigated
Aptuit (Allendale), Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 952(a) and Sec. 958(a), and in accordance with 21 CFR
1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E723978 Filed 121007; 8:45 am]
BILLING CODE 441009P
14 CFR Part 39 40 CFR Part 52 14 CFR Part 71 33 CFR Part 165 50 CFR Part 679 47 CFR Part 73 26 CFR Part 1 40 CFR Part 180 33 CFR Part 117 50 CFR Part 17 44 CFR Part 67 50 CFR Part 648 14 CFR Part 97 40 CFR Part 63 33 CFR Part 100 50 CFR Part 622 50 CFR Part 660 26 CFR Part 301 44 CFR Part 65 39 CFR Part 111 40 CFR Part 300 6 CFR Part 5 40 CFR Part 271 47 CFR Part 64 40 CFR Parts 52 and 81 50 CFR Part 665 10 CFR Part 50 44 CFR Part 64 49 CFR Part 571 39 CFR Part 3020